Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B

INTRODUCTION: In 2010, nonacog alfa became the first recombinant factor IX (rFIX) available in Japan for patients with haemophilia B. AIM: To determine real‐world safety (adverse events, incidence of inhibitors) and effectiveness of nonacog alfa in Japan. METHODS: This multicentre, prospective, obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukutake, Katsuyuki, Taki, Masashi, Matsushita, Tadashi, Sakai, Michio, Takata, Ami, Yamaguchi, Hiromi, Karumori, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852692/
https://www.ncbi.nlm.nih.gov/pubmed/31168882
http://dx.doi.org/10.1111/hae.13783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852692/
https://www.ncbi.nlm.nih.gov/pubmed/31168882
http://dx.doi.org/10.1111/hae.13783

Ejemplares similares